Evidence map›Paper›PMID 23519772›Full record

ReviewCurrent oncology reports2013

Novel immunotherapies in GU malignancies.

Alexandra Drakaki, David F McDermott

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alexandra DrakakiBeth Israel Deaconess Medical Center, 330 Brookline Ave, Rabb 430, Boston, MA, 02215, USA. adrakaki@bidmc.harvard.edu
David F McDermott

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the development of several novel therapies in recent years, genitourinary (GU) malignancies remain associated with significant morbidity and mortality. An improved understanding of how the immune system responds to cancer has led to the clinical development of several targeted immunotherapies. Data from recent clinical trials suggests that these agents might improve the prognosis of patients with advanced GU malignancies. This review article will discuss the current state of immunotherapy and describe future directions in combination therapy and biomarker development for cancers of the kidney, bladder and prostate.

Indexed as

ImmunotherapyAngiogenesis InhibitorsCancer VaccinesCarcinoma, Renal CellCombined Modality TherapyCTLA-4 AntigenFemaleHumansInterferon-alphaInterleukin-2Kidney NeoplasmsMaleNeovascularization, PathologicPrognosisProstatic NeoplasmsT-LymphocytesAngiogenesis InhibitorsCancer VaccinesCTLA-4 AntigenInterferon-alphaInterleukin-2

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.